SBIR/STTR Research Award

IN VITRO MODEL FOR MEASURING SUNSCREEN PROTECTION

Award identifier b68350f1d0c66f8fa846d6d59a233be0bf240641cff8a8dabf698c199895acb9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Mattek Corporation
Proposal award date
Not reported
Contract end date
Not reported
UEI
Q1V1JV6GJW77
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION: (Verbatim) - Excessive exposure to solar radiation results in erythema (sunburn) and has been linked to premature skin aging, immunosuppression and skin cancer. Despite greater awareness by the public of the harmful effects of exposure to sunlight and increased use of sunscreens, skin cancer rates have continued to rise. Currently accepted test methods for determining skin protection factors (SPF) of ultraviolet-B (UVB) sunscreens involve measuring increased UVB irradiation needed to cause erythema in human panelists. However, this test method is sub-optimal because of possible risk to human panelists and because the relationship between erythema and skin cancer is unclear. No method is currently accepted for determining protection provided against UVA irradiation, which is also believed to present skin cancer risks. The goal of the present proposal is to develop methodology which overcomes the drawbacks of current sunscreen testing. A mechanistic assay utilizing a highly differentiated skin model and endpoints which directly measure genotoxicity will be used. DNA strand breaks, thymine dimer photoproducts, 8-hydroxyguanosine and p53 protein expression will be determined by various convenient methods. These methods measure events directly related to skin cancer and will give producers and regulators of sunscreens important new tools for assessing the true efficacy of sunscreen formulations. Phase I research will develop methods for determining a sunscreens "DNA protection factor" - the ultimate goal of Phase II research will be to submit results of multi-lab, GLP studies to the FDA for approval as a validated method. PROPOSED COMMERCIAL APPLICATION: The proposed methods for determining genotoxicity in in vitro human skin models will find application in product safety assessment for a broad variety of pharmaceutical, chemical, and consumer product companies. Companies which produce over the counter sunscreen drug products, or other pharmaceutical, cosmetic or household consumer products which may come in contact with skin or are intended for topical use will utilize this technology.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

57 SBIR/STTR records share this UEI (1990–2020). Reported award amounts total $21,284,028. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.